Semaglutide denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Issue a "Not FDA-Approved" Denial for Semaglutide

This denial reason typically arises in one of two scenarios: (1) the requested use is an off-label indication not listed in the FDA-approved prescribing label, or (2) the specific formulation or route of administration requested differs from what is approved — for example, compounded semaglutide obtained outside of an FDA-approved product. Understanding which scenario applies to your claim is the critical first step before drafting an appeal.

## Why This Denial Is Appealable

For off-label use, federal law — including the ACA's external-review requirements (Section 2719) and ERISA's full-and-fair review standard (Section 503) — provides a right to appeal. Importantly, many state and federal laws require insurers to cover off-label uses of FDA-approved drugs when supported by peer-reviewed medical literature or recognized compendia. If the use is compounded, the appeal must address FDA's enforcement posture regarding that compound at the time of the claim. The external-review window is generally open for approximately four months following the denial notice.

## The Appeal Process

1. Identify the exact basis for the denial — request the denial letter's clinical rationale and the specific coverage policy cited. 2. File the internal appeal — confirm the deadline from your Explanation of Benefits (commonly 180 days). 3. Request independent external review if the internal appeal is denied; an IRO must evaluate whether the denial was consistent with applicable coverage standards. 4. Request expedited review if the clinical situation is urgent.

## Documentation to Gather

• Prescribing label confirmation: identify the exact FDA-approved indication(s) and, if the use is on-label, document clearly why the claim should have been processed as such.
• Off-label use support (if applicable): your prescriber should reference the applicable guideline organization (such as the ADA Standards of Care or Obesity Medicine Association guidelines) and peer-reviewed literature that supports the use — without citing specific statistics that may be misquoted.
• Medical-necessity letter: a prescriber letter explaining why this specific drug and route are necessary for this patient.
• Compendia reference (if applicable): if off-label, identify whether the use is listed in a recognized drug compendium that your state or plan is required to honor.

## Criteria-Mapping Structure

Obtain Humana's coverage policy for this drug and compare it against the FDA-approved prescribing label. Create a table with three columns: "Coverage Policy Criterion / FDA Label / Patient Record Support." If the denial rests on a misclassification of an on-label use as off-label, a single clear citation to the current prescribing label is often sufficient to resolve the appeal at the internal stage.